Describes the cutting-edge liquid biopsy technologies that promise to revolutionize oncology practice
Covers all basic approaches in the fields, with explanation of uses, benefits and limitations
Focuses on translational aspects
Part of the book series: Recent Results in Cancer Research (RECENTCANCER, volume 215)
Buy it now
Tax calculation will be finalised at checkout
Other ways to access
This is a preview of subscription content, access via your institution.
Table of contents (18 chapters)
Circulating Tumor Cells (CTC)
Circulating Tumor DNA (ctDNA)
Circulating Tumor RNA, Exosomes
About this book
This book is a comprehensive guide to the techniques, clinical applications, and benefits of the different forms of liquid biopsy employed in patients with a variety of tumor types, including lung, breast and colorectal cancer. Offering detailed explanations, it discusses the how changes in tumors can be tracked using these cutting-edge technologies, which enable the detection and analysis of diverse circulating biomarkers: tumor cells, tumor DNA, tumor RNA (free or in exosomes), and fluid biomarkers identifiable by means of targeted proteomics. The use of such advanced technologies is enabling us to tackle questions and problems in a way that was not possible just a few years ago. We now have at our disposal an effective means of overcoming the problem of intratumor heterogeneity, which has limited the value of conventional biopsy approaches. As a consequence, oncology practice is about to change radically, toward truly personalized precision medicine. This book provides both clinicians and researchers with a thorough and up-to-date overview of progress in the field.
- Liquid Biopsy
- Circulating Biomarkers
- Precision Medicine
- Circulating Tumor cells
- Circulatin Nucleic Acid
- Personalized Medicine
Editors and Affiliations
Cancéropôle Est , Strasbourg, France
Institut de Cancérologie de Lorraine, CNRS UMR7039 CRAN, Université de Lorraine, Vandoeuvre-lès-Nancy, France
Department of Hematology and Oncology, Medical Center, University of Schleswig-Holstein, Lübeck, Germany
Nikolas von Bubnoff
About the editors
Florence Schaffner obtained her PhD in Cell Biology and Biochemistry in Freiburg-im-Breisgau (Germany), in Prof. Hellmut Augustin’s angiogenesis and tumor biology lab. There, she studied in depth the role of the interaction between the receptor EphB4 and its ligand ephrinB2 during tumor angiogenesis and metastatic processes and in particular tumor cell seeding at the site of metastasis. She then took up a postdoctoral research position at Scripps Research Institute in California, under Prof. Wolfram Ruf, where she investigated the role of coagulation proteins such as tissue factor and the protease-activated receptor in tumor angiogenesis, metastasis, and cancer stem cell biology. She continued her work on cancer stem cells in France, in Dr. Dontenwill’s lab in Strasbourg. She now works at the Cancéropôle Grand-East, where she is developing new and innovative research axes in relation to translational medicine.
Jean-Louis Merlin obtained his PharmD in Lille (France) and his PhD and Research Direction degree in Nancy (France), while working in Prof. Vigneron’s lab (Faculty of Pharmacy) on innovative anticancer drug targeting in liposomes and molecular mechanisms of drug resistance in preclinical models. While head of the research lab at the Alexis Vautrin Cancer Center (now the Institut de Cancérologie de Lorraine) in Nancy, he became Professor of Cellular Oncology at the Faculty of Pharmacy. There he set up the tumor biology unit to implement the analysis of molecular tumor genetic markers in the clinical management of cancer patients. Professor Merlin coordinates the Advanced Diagnostic and Translational Research project of the CNRS research unit (UMR 7039) and the Translational Research axis at Cancéropôle Grand-East. He is also coordinating several clinical trials aiming at the validation of circulating tumor DNA as an alternative to tumor DNA for molecular diagnosis and follow-up of patients with colorectal and breast cancer, and melanoma.
Nikolas von Bubnoff obtained his MD at the Ludwig Maximilian University in Munich and gained his postdoctoral qualification at the Technical University, Munich for work describing and characterizing secondary resistance mutations of the Bcr-Abl gene in CML. While a resident at Klinikum rechts der Isar (Munich) he continued working on molecular mechanisms of treatment resistance, establishing a cell line-based screening strategy for resistance to targeted cancer treatment. Professor von Bubnoff continued his work on circulating tumor (ct)DNA in gastrointestinal stromal tumors in Freiburg, where he established routine ctDNA testing in solid tumors. There, together with Robert Zeiser, he translated this preclinical work into clinical applications. Professor von Bubnoff is currently Deputy Medical Director of the Comprehensive Cancer Center Freiburg, where he has established a molecular tumor board to make use of genome analysis to guide treatment. He is currently coordinating clinical trials on ctDNA biomarkers, treatment optimization in CML, and ruxolitinib treatment of steroid-refractory GvHD.
Book Title: Tumor Liquid Biopsies
Editors: Florence Schaffner, Jean-Louis Merlin, Nikolas von Bubnoff
Series Title: Recent Results in Cancer Research
Publisher: Springer Cham
Copyright Information: Springer Nature Switzerland AG 2020
Hardcover ISBN: 978-3-030-26438-3Published: 25 October 2019
Softcover ISBN: 978-3-030-26441-3Published: 25 October 2020
eBook ISBN: 978-3-030-26439-0Published: 11 October 2019
Series ISSN: 0080-0015
Series E-ISSN: 2197-6767
Edition Number: 1
Number of Pages: VI, 368